GLG1 (golgi glycoprotein 1) is a Golgi-localized glycoprotein that functions as an intracellular fibroblast growth factor (FGF) binding protein and decoy FGF receptor 1. As a membrane-associated protein in the Golgi apparatus, GLG1 undergoes N-glycosylation modifications that regulate its subcellular distribution and functional properties 2. Mechanistically, GLG1 expression is post-transcriptionally regulated by the m6A demethylase FTO through mRNA stability modulation 3. Additionally, GLG1 can be processed into circular RNA (circ-GLG1), which functions as a competing endogenous RNA (ceRNA) to sponge miR-346, thereby relieving post-transcriptional inhibition of KCNJ9 and activating oncogenic TGF-β, PI3K-AKT, and MAPK pathways 4. GLG1 demonstrates significant clinical relevance in multiple cancers. In gastric cancer, elevated GLG1 expression correlates with advanced stages, lymph node metastasis, and poor overall survival 3. GLG1 is upregulated in cancer stem cells and represents a potential biomarker for gastric cancer progression 5. In colorectal and bladder cancers, GLG1-derived circular RNAs promote metastatic behavior and malignant progression 64. Notably, memantine suppresses cancer cell growth partly through modulating GLG1 splicing variants and altering its cytosolic distribution, suggesting therapeutic potential through GLG1 modulation 1.